MOLECULAR SURVEILLANCE OF GONOCOCCAL CIPROFLOXACIN SUSCEPTIBILITY/RESISTANCE IN BULGARIA, 2022-2023

Abstract

Background: The emergence and spread of antimicrobial resistance in Neisseria gonorrhoeae is a significant public health issue, with Euro-GASP conducting surveillance across the EU-EEA. The advent of molecular diagnostics for N. gonorrhoeae may possibly limit the surveillance data because it is dependent on gonococcal culture for phenotypic susceptibility testing. Ideally, molecular diagnostics should combine identification and resistance detection but the complexity of gonococcal molecular genetics of resistance is a major barrier for test development. Currently, resistance prediction in N. gonorrhoeae is accurate only for fluoroquinolones and there are commercial kits available on the market that allow antimicrobial resistance surveillance and individualized treatment. The study examined Bulgaria's gonococcal fluoroquinolone resistance rate for 2022-2023 by molecular methods and compared it with previous years and EU-EEA trends. Methods: The commercial ResistancePlus® GC assay was used to predict ciprofloxacin susceptibility/resistance in 66 Neisseria gonorrhoeae-positive DNA samples from patients, diagnosed in 2022-2023. Results: The identified fluoroquinolone resistance rate in 2022-2023 was 68.2%. The majority of the cases were males in the age group 20-29 (50.8%), the most common mode of transmission was MSM (77%) and 17% of the cases with known HIV status were positive. Conclusion: This study found a higher than before fluoroquinolone resistance rate (68.2%) in Bulgaria, following the trend in Europe. In the EU-EEA, ciprofloxacin resistance increased to 65.9% in 2022. Molecular testing for predicting susceptibility/resistance is suitable for effective antimicrobial resistance surveillance and individualized treatment decisions.

Keywords

• Bulgaria
• gonorrhea
• Neisseria gonorrhoeae
• ciprofloxacin
• antimicrobial resistance